NYXH VS SHLT Stock Comparison

Performance

NYXH
10/100

NYXH returned -15.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SHLT
10/100

SHLT returned -38.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

NYXH
14/100

NYXH receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

SHLT

"Technicals" not found for SHLT

Earnings

NYXH
10/100

NYXH has missed earnings 5 times in the last 20 quarters.

SHLT

"Earnings" not found for SHLT

Profit

NYXH
10/100

Out of the last 13 quarters, NYXH has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SHLT
56/100

Out of the last 20 quarters, SHLT has had 8 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

NYXH
45/100

NYXH has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

SHLT
50/100

SHLT has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Nyxoah SA Ordinary Shares Summary

Nasdaq / NYXH

Healthcare

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

SHL Telemedicine Ltd American Depositary Shares Summary

Nasdaq / SHLT

Healthcare

Medical - Healthcare Information Services

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.

Power up your portfolio